Shattuck Labs (NASDAQ:STTK) Stock Rating Lowered by HC Wainwright

Shattuck Labs (NASDAQ:STTK) was downgraded by equities research analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a report issued on Tuesday, Briefing.com reports.

Other equities analysts have also recently issued reports about the company. Citigroup decreased their price objective on Shattuck Labs from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, August 15th. BTIG Research cut shares of Shattuck Labs from a “buy” rating to a “neutral” rating in a research note on Monday, June 17th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Shattuck Labs in a research report on Friday, August 2nd.

Shattuck Labs Trading Down 42.1 %

Shares of NASDAQ:STTK traded down $1.47 during trading on Tuesday, reaching $2.02. The company had a trading volume of 8,205,111 shares, compared to its average volume of 394,975. The company has a fifty day moving average of $3.61 and a two-hundred day moving average of $6.12. The stock has a market capitalization of $96.41 million, a P/E ratio of -1.03 and a beta of 1.72. Shattuck Labs has a 12 month low of $1.33 and a 12 month high of $11.76.

Shattuck Labs (NASDAQ:STTK) last released its earnings results on Thursday, August 1st. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). Shattuck Labs had a negative net margin of 2,067.99% and a negative return on equity of 68.65%. The firm had revenue of $1.61 million during the quarter, compared to the consensus estimate of $0.50 million. Shattuck Labs’s revenue was up 704.5% compared to the same quarter last year. As a group, equities research analysts predict that Shattuck Labs will post -1.72 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company bought a new position in shares of Shattuck Labs during the second quarter valued at about $67,000. Cannon Global Investment Management LLC purchased a new stake in Shattuck Labs in the 1st quarter worth approximately $91,000. Virtu Financial LLC bought a new stake in shares of Shattuck Labs in the 1st quarter worth approximately $113,000. Acadian Asset Management LLC bought a new position in shares of Shattuck Labs during the second quarter valued at approximately $170,000. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in Shattuck Labs in the first quarter worth $174,000. 58.74% of the stock is owned by hedge funds and other institutional investors.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.